GEHC vs JNJ
Valuation
Profitability
Growth
Financial Health
Dividends
AI Verdict
GEHC presents a stark contrast between analyst optimism and deterministic fundamental health. The Piotroski F-Score of 3/9 indicates weak financial health, and the current price of $72.91 trades at a significant premium to both the Graham Number ($48.02) and the Intrinsic Value ($31.50). While the company maintains strong ROE (22.38%) and consistent earnings beats, the negative YoY earnings growth (-17.70%) and bearish technical trend suggest a period of instability. The stock is fundamentally overvalued based on deterministic models, though it remains cheaper than the broader healthcare sector average P/E.
JNJ shows neutral fundamentals based on deterministic rules. Financial strength is weak (F-Score 3/9). Mixed signals with both opportunities and risks present.
Compare Another Pair
Related Comparisons
GEHC vs JNJ: Head-to-Head Comparison
This page compares GE HealthCare Technologies Inc. (GEHC) and Johnson & Johnson (JNJ) across key fundamental metrics including valuation ratios, profitability margins, growth rates, financial health indicators, and dividend metrics. Each metric highlights the better-performing stock so you can quickly identify relative strengths and weaknesses.
Our AI engine independently analyzes each company's financials, competitive position, and market conditions to produce a verdict (Bullish, Neutral, or Bearish) along with key strengths and risks. Use this comparison alongside your own research to make informed investment decisions.